Trials Offered by a Specific Doctor

HERBERT IRVING COMPREHENSIVE CANCER CENTER
Investigator
Naiyer Rizvi, MD
Email
nar2144@cumc.columbia.edu

Dr. Rizvi is the director of thoracic oncology and director of immunotherapeutics for the division of Hematology and Oncology at Columbia University Medical Center.

He also holds the Price Chair in Clinical Translational Research.

He is an internationally recognized leader in the treatment of lung cancer and immunotherapy drug development. Prior to joining Columbia University Medical Center, his clinical research at Memorial Sloan Kettering Cancer played a significant role in the FDA approval path of a new class of immunotherapies, called immune checkpoint inhibitors, for melanoma and lung cancer.

His research focus is studying mechanisms of sensitivity and resistance to immunotherapy. Through genetic testing of tumors, he has been able to improve the understanding of why immune checkpoint inhibitors work in certain patients. This work has been partially supported by Stand Up To Cancer -- Cancer Research Institute Immunology funding.

In his research, he also is studying why certain cancers do not respond to immune checkpoint inhibitors, so we can find better ways to harness the immune system to attack cancer cells. He oversees phase 1 immunotherapy research in solid tumors at Columbia University Medical Center and is conducting key clinical studies of novel immunotherapy drugs and immunotherapy combinations to help more patients in the fight against cancer.


Clinical Studies Managed By Dr. Rizvi:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study for patients with locally advanced or metastatic non-small cell lung cancer using study drug AZD9291AstraZenecaAAAO0858
Details[CLOSED] A study for patients with advanced or metastatic lung cancer using study drug NivolumabBristol-Myers SquibbAAAO8208
Details[CLOSED] Study for patients with advanced Non-small Cell Lung Cancer using study drug MEDI4736MedImmuneAAAP0151
Details[CLOSED] A study for patients with advanced cancers using study drugs MEDI0680 and MEDI4736MedImmuneAAAO9503
Details[CLOSED] A study for patients with advanced or metastatic solid tumors using study drug ulocuplumab combined with nivolumabBristol-Myers SquibbAAAP5904
Details[CLOSED] A study for patients with advanced Non-Small-Cell Lung Cancer (NSCLC) using study drug MEDI4736 in combination with TremelimumabAstraZenecaAAAP9838
Details[CLOSED] A study for patients with advanced solid tumors using study drug MEDI0562AstraZenecaAAAQ4411
DetailsA study to identify the benefits of study drug pembrolizumab in patients with advanced or recurrent cancersMerckAAAQ5450
DetailsA study for patients with advanced cancers using study drugs PF-04518600 and PF-05082566PfizerAAAQ8228
DetailsAdjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)The AllianceAAAO6500
DetailsStudy of Treatment Combinations in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) (Morpheus-Lung)F. Hoffman- La Roche LtdAAAR5551
Details[CLOSED] Study of Drug vs. Placebo in Patients with Early Stage Non-Small Cell Lung Cancer (NSCLC)ECOG- ACRINAAAO9704
DetailsStudy of a New Treatment in Patients with Non-Small Cell Lung CancerGenentech, Inc.AAAR6740
DetailsStudy of Drug in Patients with Early Stage Non-Small Cell Lung CancerECOG- ACRINAAAQ9672
DetailsHUDSON: Study of Multiple Treatments in Patients with Non-Small Cell Lung Cancer (NSCLC)AstraZenecaAAAR6575
DetailsExploratory Biopsy Sample Study of Metastatic CancerGenentech, Inc.AAAR5089
Details[CLOSED] Study of Drug in Non-Small Cell Lung CancerF. Hoffmann- La Roche Ltd.AAAR5186
DetailsStudy of Experimental Drug GSK3359609 in Patients with Advanced Solid TumorsGlaxoSmithKlineAAAR8356
DetailsBiomarker-Driven Study for Second Line Therapy of Squamous Cell Lung Cancer (Lung-MAP)Southwest Oncology GroupAAAO0305
DetailsStudy of Combinations of REGN2810, Chemotherapy, and Ipilimumab vs. Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung CancerRegeneron Pharmaceuticals, Inc.AAAR7798
DetailsStudy of Nivolumab Alone or in Combination with Ipilimumab for the Treatment of Patients with Advanced Hypermutated Solid TumorsCanadian Cancer Trials GroupAAAR9508